In March 2017, the U.S. Food and Drug Administration (FDA) inspected Transcoject GmbH for the second time since 2015 in the course of a routine inspection. The inspection lasted four days as initially planned. It confirmed the facility to be compliant with the principles and guidelines of Good Manufacturing Practices (GMP) and only one marginal observation was issued. At the closing meeting the inspector informed that he was very satisfied with what he had seen.

At Transcoject, we are committed to supporting our customers in their effort to enhance patient safety whilst maintaining the highest quality standards. Thus, you can focus on what really matters: bringing products to market fast and efficiently.